Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 20;22(5):324-328.
doi: 10.3779/j.issn.1009-3419.2019.05.10.

[Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation]

[Article in Chinese]
Xin Wang  1 , Diansheng Zhong  1
Affiliations
Review

[Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation]

[Article in Chinese]
Xin Wang et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

With the development of sequencing technology, the detection rate of de novo T790M mutation is increasing. The emergence of the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide treatment opportunities. Secondary T790M mutation is often emphasized in clinic, but de novo T790M mutation is neglected. This review found that the incidence of de novo T790M mutation fluctuated greatly, which was mainly affected by sequencing techniques. The de novo T790M mutation is mainly low in mutation abundance, easy to combine with other gene changes, a poor predictor and prognostic factor and the efficacy of the first and second generation EGFR-TKIs is limited. The therapeutic value of osimertinib needs to be studied. .

【中文题目：原发T790M突变非小细胞肺癌研究进展】 【中文摘要：随着检测技术的发展，原发T790M突变检出率不断增加，三代表皮生长因子受体（epidermal growth factor receptor, EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）出现为其提供治疗机会。临床常重视继发T790M突变，而对原发T790M突变忽视或关注度不够。本综述发现原发T790M突变发生率波动大，主要受检测技术影响。原发T790M突变丰度多较低，易合并其他基因改变，是不良的预测和预后指标，一代和二代EGFR-TKIs疗效欠佳，奥希替尼的治疗价值有待研究。 】 【中文关键词：肺肿瘤；表皮生长因子受体；T790M】.

Keywords: Epidermal growth factor receptor (EGFR); Lung neoplasms; T790M.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Zhong J, Li L, Wang Z, et al. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) J Thorac Oncol. 2017;12(12):1766–1778. doi: 10.1016/j.jtho.2017.07.032. - DOI - PubMed
    1. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi: 10.1158/1078-0432.CCR-12-2246. - DOI - PMC - PubMed
    1. Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2011;3(1):10–18. doi: 10.3978/j.issn.2072-1439.2010.12.02. - DOI - PMC - PubMed
    1. Ohashi K, Maruvka YE, Michor F, et al. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013;31(8):1070–1080. doi: 10.1200/JCO.2012.43.3912. - DOI - PMC - PubMed
    1. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–377. doi: 10.1056/NEJMoa0800668. - DOI - PMC - PubMed

MeSH terms